Angina Pectoris Treatment Market: Growth Opportunities Created by Covid19 Outbreak

The global “angina pectoris treatment market size” is anticipated to gain impetus from the increasing awareness programs regarding the availability of several therapy options. Fortune Business Insights, in an upcoming report, titled, “Angina Pectoris Treatment Market Size, Share and Global Trend By Drug Class (Beta Blockers, Calcium Antagonists, Anti-coagulants, Anti-Platelets), Disease Type (Stable or chronic angina, Unstable angina, Variant and microvascular angina), Distribution Channel (Online pharmacies, Hospital pharmacies, Retail pharmacies) and Geography Forecast till 2026,” rising per capita healthcare spending, availability of personalized medicine, and surge in the economies are expected to boost the global angina pectoris treatment market growth in the coming years. Moreover, a rising number of upcoming pipelines for potential candidates will also contribute to growth.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/angina-pectoris-treatment-market-100377

Key Players Operating in The Angina Pectoris Treatment Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Abbott
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Hoffmann-La Roche Ltd
  • ALLERGAN
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

New Innovative Product Launches to Favor Growth in North America

The global angina pectoris treatment market is geographically divided into Latin America, Asia Pacific, Europe, the Middle East and Africa, and North America. Out of these, North America is projected to lead the global market during the forecast period. It would occur due to the introduction of several guidelines involved in managing and diagnosing patients suffering from stable ischemic heart disease. New product launches also contribute to the growth in this region. Asia Pacific, on the other hand, is considered to remain in the second-fastest-growing market due to the rising economies in the healthcare sector.

AstraZeneca Enters into Strategic Collaboration with Recordati to Deliver Seloken in Europe

AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, headquartered in the U.K., announced that it has partnered up with Recordati, an Italy-based pharmaceutical company in May 2017. The main of the collaboration is to gain commercial rights to Seloken ZOK (metoprolol succinate) and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate aids in controlling heart failure, angina, and hypertension. AstraZeneca received a payment of USD 300 from Recordati after the completion of this partnership. AstraZeneca will develop and supply the medicines to the latter under another supply agreement. Product sales for Logimax and Seloken brands were USD 100 million in Europe, in 2016. AstraZeneca will commercialize these medicines in all the markets where it holds the rights.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/customization/angina-pectoris-treatment-market-100377

Order Full Report: https://www.fortunebusinessinsights.com/checkout-page/100377

SEGMENTATION

By Drug Class

  • Beta-Blockers
  • Calcium Antagonists
  • Anti-coagulants
  • Anti-Platelets
  • Nitrates
  • Anti-Angina
  • ACE inhibitors

By Disease Type

  • Stable or chronic angina
  • Unstable angina
  • Variant and microvascular angina

By Distribution Channel

  • Online pharmacies
  • Hospital pharmacies
  • Retail pharmacies

By Geography

  • North America (the USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Published
Categorized as Healthcare

By Industry Research Reports

Our market studies encompass a multitude of factors such as market, economic and technological developments. They contain a detailed study on various market segments. Information thus included is obtained via extensive desk research and interviews with relevant stakeholders.

Leave a comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Create your website with WordPress.com
Get started
%d bloggers like this: